KalVista Pharmaceuticals has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $160,100,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, KalVista Pharmaceuticals is raising $160,100,000.00 in new funding. About KalVista Pharmaceuticals: KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
To learn more about KalVista Pharmaceuticals, visit http://www.kalvista.com/
Contact:
Thomas Crockett, Chief Executive Officer
857-999-0075
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.